Howard McLeod: Preemptive DPYD Testing Program for patients planned for a systemic Fluoropyrimidine

 Howard McLeod, Central Director, Founder and Advisor at Precision Medicine, shared on LinkedIn:

“The USA cancer community might be late to adopt Dihydropyrimidine dehydrogenase (DPYD) testing to avoid severe/fatal toxicity from commonly used chemotherapy, but the tide has finally changed. The recent Food and Drug Administration (FDA) package insert change is followed by very successful implementation at Dana-Farber Cancer Institute. With data from community centers, such as Atrium Health and St. Elizabeth Healthcare, there are no more excuses for rest of the field.”

Additional information
Source: Howard McLeod/LinkedIn